Oxford BioDynamics (LON:OBD) Shares Down 6.1% – Here’s Why

Shares of Oxford BioDynamics Plc (LON:OBD) were down 6.1% during trading on Friday . The company traded as low as GBX 0.27 and last traded at GBX 0.28. Approximately 71,899,195 shares changed hands during mid-day trading, an increase of 151% from the average daily volume of 28,636,674 shares. The stock had previously closed at GBX 0.30.

Analyst Ratings Changes

Separately, Shore Capital reiterated a “house stock” rating on shares of Oxford BioDynamics in a research note on Wednesday, October 8th.

Oxford BioDynamics Stock Down 13.9%

The company has a quick ratio of 2.80, a current ratio of 0.68 and a debt-to-equity ratio of 370.22. The stock has a 50 day simple moving average of GBX 0.39 and a 200 day simple moving average of GBX 0.41. The stock has a market cap of £4.97 million, a price-to-earnings ratio of -0.09 and a beta of 0.42.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.